睿智医药收盘上涨13.15%，最新市净率4.74，总市值57.86亿元

Group 1 - The core viewpoint of the news is that Ruizhi Pharmaceutical's stock has seen a significant increase of 13.15% on June 3, closing at 11.62 yuan, while its market-to-book ratio has reached a new low of 4.74 in 596 days, with a total market value of 5.786 billion yuan [1] - The company experienced a net outflow of main funds amounting to 248.0084 million yuan on June 3, and over the past five days, the total outflow reached 92.6886 million yuan [1] - Ruizhi Pharmaceutical specializes in providing drug discovery, development, and production services to global pharmaceutical companies, biotechnology firms, and research institutions, with its main products including chemical business, pharmacodynamics, and macromolecule business [1] Group 2 - The latest financial report for the first quarter of 2025 shows that the company achieved an operating income of 261 million yuan, representing a year-on-year increase of 11.37%, and a net profit of 6.6421 million yuan, which is a year-on-year increase of 126.09%, with a sales gross margin of 27.44% [1] - In comparison to industry averages, Ruizhi Pharmaceutical's PE (TTM) is -29.77, PE (static) is -25.55, and its market-to-book ratio is 4.74, while the industry average PE (TTM) is 40.35 and the industry median is 47.21 [2] - The total market value of Ruizhi Pharmaceutical is 5.786 billion yuan, which is lower than the industry median market value of 59.39 billion yuan [2]